Retatrutide

Weight loss is the main reason Retatrutide has attracted so much attention. In the Phase 2 obesity trial, the 12 mg group lost 24.2% of their starting weight on average at 48 weeks. More recently, Lilly reported an average 28.3% reduction at 80 weeks in the 12 mg group of the Phase 3 TRIUMPH-1 trial. To put 24.2% into everyday terms, 100 kg of starting weight would correspond to about 24 kg (53 lb) on that trial average — not a prediction of what any individual would lose.

In the 48-week obesity study, the 12 mg group lost 24.2% of their starting body weight on average, compared with 2.1% in the placebo group.

Retatrutide is not only being studied for the number on the scales. Its hormone effects also influence the way the body handles glucose. Human studies in type 2 diabetes have reported meaningful improvements in blood-sugar control, while obesity research has also shown changes in measures such as fasting glucose, insulin, blood pressure and lipids.

In a diabetes study, the higher-dose group had a sizeable fall in HbA1c — a blood test that shows average blood-sugar levels over the previous few months.

A large part of the appeal is what may happen around eating itself. Retatrutide acts on hormone pathways involved in hunger and fullness, so a person may become satisfied with less food and find a lower food intake easier to maintain. This is also why ideas such as quieter ‘food noise’, fewer persistent thoughts about food and less pull from cravings feature so heavily in community discussion.

Retatrutide acts on hormone pathways involved in hunger, fullness and how the body handles energy. These effects may help explain the weight loss seen in trials.

Weight tells only part of the story. The Phase 2 obesity study also recorded substantial reductions in waist circumference, while the wider clinical programme is examining obesity-related health problems. For a newcomer, the important point is that the interest is not simply in becoming lighter — it is in whether losing substantial excess weight translates into meaningful changes in body shape, mobility and metabolic health.

Clinical development includes type 2 diabetes, obesity, cardiovascular disease, knee osteoarthritis and outcomes populations with cardiovascular or kidney disease.

Semaglutide targets GLP-1 and tirzepatide targets GLP-1 plus GIP. Retatrutide adds a third target: the glucagon receptor. Researchers are interested in whether that extra pathway can influence energy expenditure and the way the body uses stored fuel as well as appetite. Exactly how much this contributes to the overall weight-loss effect is still being worked out.

This part of the story is less settled than the weight-loss results. Researchers are still working out how much the third hormone pathway contributes in people.

The next stage of the Retatrutide story is about what substantial weight loss may mean beyond appearance. Phase 3 research has been examining obesity alongside conditions including type 2 diabetes, knee osteoarthritis and obstructive sleep apnoea. That matters because the most valuable outcome is not simply a smaller number on the scales, but whether people move, sleep and function better as their health changes.

Larger studies are examining health outcomes in people with obesity and related conditions. Those questions need their own results rather than being assumed from weight loss alone.